Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61.


Ressource 1Download: 31672144_BIB_BC6FED59C661.pdf (2032.88 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
Article: article from journal or magazin.
Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61.
Cardiovascular diabetology
Winzap P., Davies A., Klingenberg R., Obeid S., Roffi M., Mach F., Räber L., Windecker S., Templin C., Nietlispach F., Nanchen D., Gencer B., Muller O., Matter C.M., von Eckardstein A., Lüscher T.F.
1475-2840 (Electronic)
Publication state
Issued date
Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Hyperglycemia in the setting of an acute coronary syndrome (ACS) impacts short term outcomes, but little is known about longer term effects. We therefore designed this study to firstly determine the association between hyperglycemia and short term and longer term outcomes in patients presenting with ACS and secondly evaluate the prognostic role of diabetes, body mass index (BMI) and the novel biomarker Cyr61 on outcomes.
The prospective Special Program University Medicine-Acute Coronary Syndrome (SPUM-ACS) cohort enrolled 2168 patients with ACS between December 2009 and October 2012, of which 2034 underwent PCI (93.8%). Patients were followed up for 12 months. Events were independently adjudicated by three experienced cardiologists. Participants were recruited from four tertiary hospitals in Switzerland: Zurich, Geneva, Lausanne and Bern. Participants presenting with acute coronary syndromes and who underwent coronary angiography were included in the analysis. Patients were grouped according to history of diabetes (or HbA1c greater than 6%), baseline blood sugar level (BSL; < 6, 6-11.1 and > 11.1 mmol/L) and body mass index (BMI). The primary outcome was major adverse cardiac events (MACE) which was a composite of myocardial infarction, stroke and all-cause death. Secondary outcomes included the individual components of the primary endpoint, revascularisations, bleeding events (BARC classification) and cerebrovascular events (ischaemic or haemorrhagic stroke or TIA).
Patients with hyperglycemia, i.e. BSL ≥ 11.1 mmol/L, had higher levels of C-reactive protein (CRP), white blood cell count (WBC), creatinine kinase (CK), higher heart rates and lower left ventricular ejection fraction (LVEF) and increased N-terminal pro-brain natriuretic peptide. At 30 days and 12 months, those with BSL ≥ 11.1 mmol/L had more MACE and death compared to those with BSL < 6.0 mmol/L or 6.0-11.1 mmol/L (HR-ratio 4.78 and 6.6; p < 0.001). The novel biomarker Cyr61 strongly associated with high BSL and STEMI and was independently associated with 1 year outcomes (HR 2.22; 95% CI 1.33-3.72; Tertile 3 vs. Tertile 1).
In this large, prospective, independently adjudicated cohort of in all comers ACS patients undergoing PCI, both a history of diabetes and elevated entry glucose was associated with inflammation and increased risk of MACE both at short and long-term. The mediators might involve increased sympathetic activation, inflammation and ischemia as reflected by elevated Cyr61 levels leading to larger levels of troponin and lower LVEF. Trial registration Clinical Trial Registration Number: NCT01000701. Registered October 23, 2009.
Acute Coronary Syndrome/blood, Acute Coronary Syndrome/mortality, Acute Coronary Syndrome/physiopathology, Acute Coronary Syndrome/therapy, Aged, Biomarkers/blood, Blood Glucose/metabolism, Body Mass Index, Cysteine-Rich Protein 61/blood, Diabetes Mellitus/blood, Diabetes Mellitus/mortality, Diabetes Mellitus/therapy, Female, Glycated Hemoglobin A, Humans, Hyperglycemia/blood, Hyperglycemia/mortality, Hyperglycemia/therapy, Inflammation/blood, Inflammation/mortality, Inflammation/therapy, Inflammation Mediators/blood, Male, Middle Aged, Percutaneous Coronary Intervention, Prognosis, Prospective Studies, Risk Assessment, Risk Factors, Stroke Volume, Switzerland, Time Factors, Ventricular Function, Left, Acute coronary syndromes, Diabetes, Glucose, Inflammation, Major cardiovascular and cerebrovascular events, Mortality
Web of science
Open Access
Create date
02/11/2019 23:51
Last modification date
30/04/2021 7:14
Usage data